Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors

References

• Le BT, Kumarasiri M, Adams JRJ, et al. Targeting Pim kinases for cancer treatment: opportunities and challenges. Future Med Chem 2015;7:35–53.
   PubMed Web of Science ®Google Scholar
• Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev 2014;34:136–59.
   PubMed Web of Science ®Google Scholar
• Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23–34.
   PubMed Web of Science ®Google Scholar
• Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37:141–50.
   PubMed Web of Science ®Google Scholar
• Tursynbay Y, Zhang J, Li Z, et al. Pim-1 kinase as cancer drug target: an update (Review). Biomed Rep 2016;4:140–6.
   PubMed Web of Science ®Google Scholar
• Keane NA, Reidy M, Natoni A, et al. Targeting the Pim kinases in multiple myeloma. Blood Cancer J 2015;5:e325.
   PubMed Web of Science ®Google Scholar
• Foulks JM, Carpenter KJ, Luo B, et al. A small-molecule inhibitor of pim kinases as a potential treatment for urothelial carcinomas. Neoplasia 2014;16:403–12.
   PubMed Web of Science ®Google Scholar
• Decker S, Finter J, Forde A, et al. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther 2014;13:1231–45.
   PubMed Web of Science ®Google Scholar
• Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013;122:1610–20.
   PubMed Web of Science ®Google Scholar
• Drygin D, Haddach M, Pierre F, Ryckman DM. Potential use of selective and nonselective pim kinase inhibitors for cancer therapy. J Med Chem 2012;55:8199–208.
   PubMed Web of Science ®Google Scholar
• Guo S, Mao X, Chen J, et al. Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res 2010;29:161–7.
   PubMed Web of Science ®Google Scholar
• Brault L, Gasser C, Bracher F, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004–15.
   PubMed Web of Science ®Google Scholar
• Merke AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 2012;21:425–36.
   PubMed Web of Science ®Google Scholar
• Morwick T. Pim kinase inhibitors: a survey of the patent literature. Expert Opin Ther Patents 2010;20:193–212.
   PubMed Web of Science ®Google Scholar
• Arunesh GM, Shanthi E, Krishna MH, et al. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update. Expert Opin Ther Patents 2014;24:5–17.
   PubMed Web of Science ®Google Scholar
• Qian K, Wang L, Cywin CL, et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009;52:1814–27.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bayakhmetov S. PIM1 kinase as a promise of targeted therapy in prostate cancer stem cells (Review). Mol Clin Oncol 2016;4:13–17.
   PubMed Web of Science ®Google Scholar
• Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2014;123:905–13.
   PubMed Web of Science ®Google Scholar
• Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010;70:10288–98.
   PubMed Web of Science ®Google Scholar
• Pierre F, Stefan E, Nédellec AS, et al. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett 2011;21:6687–92.
   PubMed Web of Science ®Google Scholar
• Garcia PD, Langowski JL, Wang Y, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematological cancers. Clin Cancer Res 2014;20:1834–45.
   PubMed Web of Science ®Google Scholar
• Burger MT, Han W, Lan J, et al. Structure guided optimization, in vitro, in vivo activity, and activity of Pan-PIM kinase inhibitors. ACS Med Chem Lett 2013;4:1193–7.
   PubMed Web of Science ®Google Scholar
• Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 Kinase. J Biol Chem 2005;280:6130–7.
   PubMed Web of Science ®Google Scholar
• Naguib BH, El-Nassan HB. Synthesis of new thieno[2,3-b]pyridine derivatives as pim-1 inhibitors. J Enzyme Inhib Med Chem 2016;31:1718–25.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Hirth B, Asmussen G, et al. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. Bioorg Med Chem Lett 2011;21:3050–6.
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Pim kinase inhibitors as cancer chemotherapeutics. WO2008082839; 2008.
   Google Scholar
• Tao Z-F, Hasvold L, Leverson JD, et al. Discovery of 3H-Benzo[4,5]thieno[3,2-d]pyrimidine-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem 2009;52:6621–36.
   PubMed Web of Science ®Google Scholar
• Exelixis, Inc. Benzofuropyrimidinones as protein kinase inhibitors. WO2009086264; 2009.
   Google Scholar
• Tsuhako AL, Brown DS, Koltun ES, et al. The design, synthesis, and biological evaluation of PIM kinase inhibitors. Bioorg Med Chem Lett 2012;22:3732–8.
   PubMed Web of Science ®Google Scholar
• Madkour HMF, Afify AAE, Abdalha AA, et al. Synthetic utility of enaminonitrile moiety in heterocyclic synthesis: synthesis of some new thienopyrimidines. Phosphorus Sulfur Silicon Relat Elem 2009;184:719–32.
   Web of Science ®Google Scholar
• Stroganova TA, Vasilin VK, Zelenskaya EA, et al. Some transformations of tertiary N-furfurylamides of aromatic and heteroaromatic carboxylic acids under acidic conditions. Synthesis 2008;19:3088–98.
   Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Scudiere DA, Shoemaker RH, Paul KD, et al. Evaluation of a soluble Tetrazolium/Formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827–33.
   PubMed Web of Science ®Google Scholar